Trump’s first 100 days tout US-bound pharma investments amid tariff worries
While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for the sector.
Donald Trump’s first 100 days: Impact on the healthcare industry
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
FDA approves AbbVie’s upadacitinib for giant cell arteritis
AstraZeneca’s Truqap fails in another Phase III trial
Impending US tariffs signal uncertain future for global pharma, says GlobalData
Analysis
View More
Themes
View MoreAstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans